Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.65 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.65 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | BCL6 | P41182 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4223630 | 1.00 | GRM2 (0.65) | GRM2GRM3PDCD1LG2CD274BCHE | |
| SCHEMBL954726 | 0.88 | GRM2 (0.68) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL954728 | 0.88 | GRM2 (0.68) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL950893 | 0.88 | GRM2 (0.71) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL950892 | 0.88 | GRM2 (0.71) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL4219788 | 0.83 | GRM2 (0.80) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL4219784 | 0.83 | GRM2 (0.80) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL953673 | 0.82 | GRM2 (0.85) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL955657 | 0.82 | GRM2 (0.85) | GRM2GRM3BCHEACHEBACE1 | |
| SCHEMBL952373 | 0.82 | GRM2 (0.71) | GRM2GRM3PDCD1LG2CD274BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868014-B2 | 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists | ELI LILLY AND COMPANY (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | ELI LILLY AND COMPANY (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300266-A1 | 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists | GRM3, GRM1, GRIA3 | GRM2 5/4885GRM3 1/4885PDCD1LG2 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.